Rachid Baz

8.4k total citations
183 papers, 3.7k citations indexed

About

Rachid Baz is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Rachid Baz has authored 183 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Hematology, 105 papers in Molecular Biology and 81 papers in Oncology. Recurrent topics in Rachid Baz's work include Multiple Myeloma Research and Treatments (135 papers), Protein Degradation and Inhibitors (59 papers) and Cancer Treatment and Pharmacology (42 papers). Rachid Baz is often cited by papers focused on Multiple Myeloma Research and Treatments (135 papers), Protein Degradation and Inhibitors (59 papers) and Cancer Treatment and Pharmacology (42 papers). Rachid Baz collaborates with scholars based in United States, Canada and Denmark. Rachid Baz's co-authors include Mohamad A. Hussein, Kenneth H. Shain, Melissa Alsina, Daniel M. Sullivan, Toni K. Choueiri, Faith E. Davies, Paul G. Richardson, Mary Ann Karam, Beth Faiman and Brian I. Rini and has published in prestigious journals such as Circulation, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Rachid Baz

176 papers receiving 3.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rachid Baz United States	32	2.3k	2.1k	1.6k	595	337	183	3.7k
Raman Desikan United States	18	3.5k 1.5×	2.6k 1.2×	1.8k 1.1×	684 1.1×	197 0.6×	35	4.5k
Mohamad A. Hussein United States	33	2.5k 1.1×	2.2k 1.0×	2.2k 1.4×	916 1.5×	335 1.0×	129	4.8k
Martin Kaiser United Kingdom	39	2.9k 1.3×	3.0k 1.4×	2.0k 1.2×	403 0.7×	186 0.6×	208	4.8k
Natalie S. Callander United States	41	4.0k 1.7×	3.2k 1.5×	2.8k 1.7×	716 1.2×	265 0.8×	199	5.9k
Jeffrey A. Zonder United States	35	2.7k 1.2×	2.9k 1.4×	1.9k 1.2×	661 1.1×	182 0.5×	194	4.6k
Thomas Pabst Switzerland	30	2.5k 1.1×	1.6k 0.8×	1.2k 0.7×	713 1.2×	307 0.9×	180	4.3k
Luciano J. Costa United States	35	3.2k 1.4×	1.9k 0.9×	2.4k 1.5×	619 1.0×	223 0.7×	256	4.8k
Athanasios Fassas United States	41	5.0k 2.2×	2.9k 1.4×	2.5k 1.6×	805 1.4×	282 0.8×	79	6.1k
Chaim Shustik Canada	29	2.5k 1.1×	2.0k 0.9×	1.9k 1.2×	1.0k 1.7×	273 0.8×	74	4.5k
Stefan Knop Germany	33	1.9k 0.8×	1.9k 0.9×	2.1k 1.3×	396 0.7×	273 0.8×	152	4.4k

Countries citing papers authored by Rachid Baz

Since Specialization

Citations

This map shows the geographic impact of Rachid Baz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachid Baz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachid Baz more than expected).

Fields of papers citing papers by Rachid Baz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachid Baz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachid Baz. The network helps show where Rachid Baz may publish in the future.

Co-authorship network of co-authors of Rachid Baz

This figure shows the co-authorship network connecting the top 25 collaborators of Rachid Baz. A scholar is included among the top collaborators of Rachid Baz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachid Baz. Rachid Baz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hoffman, James E., Naresh Bumma, Joshua Richter, et al.. (2025). Patient-Reported Quality of Life with Linvoseltamab in Triple-Class Exposed Patients with Relapsed/Refractory Multiple Myeloma: 2-year Results from the LINKER-MM1 Phase 1/2 Clinical Trial. Clinical Lymphoma Myeloma & Leukemia. 25. S116–S116. 1 indexed citations

Williams, Roy, Samuel M. Rubinstein, Timothy J. Garrett, et al.. (2024). Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma. Clinical and Translational Science. 17(5). e13828–e13828. 1 indexed citations

Meads, Mark B., Xiaohong Zhao, David Noyes, et al.. (2024). De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression. Blood. 144(Supplement 1). 1906–1906.

Grajales‐Cruz, Ariel, Doris K. Hansen, Brandon Blue, et al.. (2024). P-027 Real World Experience of Standard of Care Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S56–S56. 1 indexed citations

Puglianini, Omar Castañeda, Doris K. Hansen, Brandon Blue, et al.. (2024). Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.. Journal of Clinical Oncology. 42(16_suppl). 7524–7524. 1 indexed citations

Freeman, Ciara L., Meghan Menges, Hien Liu, et al.. (2023). Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis after Four Prior Lines. Blood. 142(Supplement 1). 1931–1931. 1 indexed citations

Freeman, Ciara L., Meghan Menges, Jeffrey Edelman, et al.. (2023). Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. Clinical Cancer Research. 29(22). 4575–4585. 8 indexed citations

Freeman, Ciara L., Xiaohong Zhao, Mark B. Meads, et al.. (2023). Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease. Blood. 142(Supplement 1). 3304–3304. 3 indexed citations

Sahebjam, Solmaz, Nam Tran, Rachid Baz, et al.. (2022). Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma. OncoTargets and Therapy. Volume 15. 953–962. 4 indexed citations

10.

Yoo, Kwai Han, Dok Hyun Yoon, Hye Jin Kang, et al.. (2021). Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features. Current Problems in Cancer. 46(1). 100788–100788. 1 indexed citations

11.

Ghobrial, Irene M., Chia‐Jen Liu, Robert Redd, et al.. (2019). A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clinical Cancer Research. 26(2). 344–353. 79 indexed citations

12.

Kuruvilla, John, Michael R. Savona, Rachid Baz, et al.. (2017). Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 129(24). 3175–3183. 112 indexed citations

13.

Baz, Rachid, Jeffrey A. Zonder, Kenneth H. Shain, et al.. (2017). Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM). Blood. 130. 3095–3095. 7 indexed citations

14.

Yun, Seongseok, et al.. (2017). Waldenström Macroglobulinemia: Review of Pathogenesis and Management. Clinical Lymphoma Myeloma & Leukemia. 17(5). 252–262. 31 indexed citations

15.

Ribeiro, Maria L.C., Timothy Jacobson, Lori Hazlehurst, et al.. (2013). A Preclinical Assay for Chemosensitivity in Multiple Myeloma. Cancer Research. 74(1). 56–67. 42 indexed citations

16.

Baz, Rachid, Hui‐Yi Lin, Sung‐Soo Yoon, et al.. (2013). Response Adapted Lenalidomide Based Therapy For Newly Diagnosed (ND) Standard Risk Older Adults With Multiple Myeloma (MM): An International Collaboration. Blood. 122(21). 3201–3201. 1 indexed citations

17.

Nishihori, Taiga, et al.. (2013). Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: A Focus on Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 19(8). 1144–1151. 10 indexed citations

18.

Boucher, Kelly, Raymond Widen, Kenneth H. Shain, et al.. (2012). Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow. Clinical Cancer Research. 18(22). 6155–6168. 69 indexed citations

19.

Emmons, Michael F., Rajesh R. Nair, Rachid Baz, et al.. (2011). Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved α4 Integrin Expression and a Compromised CAM-DR Phenotype. Molecular Cancer Therapeutics. 10(12). 2257–2266. 24 indexed citations

20.

Baz, Rachid, Esteban Walker, Mohamed A. Karam, et al.. (2006). Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Annals of Oncology. 17(12). 1766–1771. 116 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact